Posted 23 Feb. 2023 at 07:17 PMUpdated Feb 23. 2023 at 07:28 PM
The biotech sector, which had found itself in the spotlight during the health crisis, suffered a severe setback in 2022.
In the United States, the S&P Biotech fell 27% in an environment hostile to technology stocks. After the successes of Moderna and BioNTech, which provided the world with messenger RNA vaccines once morest Covid in record time, the euphoria has subsided. These two biotech stars, still unknown three years ago, have seen their stock prices halve from the peaks of August 2021, but they still post impressive valuations of, respectively, 58 billion and 32 billion. dollars.